Neurological
Refine Search
Biotechnology
New York-based cell and gene therapy specialist Axovant Sciences has agreed a new strategic partnership with Yposkesi, a Contract Development & Manufacturing Organization (CDMO) specializing in gene therapy vector manufacturing. 28 November 2018
Biotechnology
Shares in US gene therapy specialist Rocket Pharmaceuticals rose by 9% in the opening 90 minutes of trading on Monday. 26 November 2018
Pharmaceutical
People with Alzheimer’s disease using strong opioids have twice the risk of hip fracture compared to non-opioid users, a new study from the University of Eastern Finland shows. 26 November 2018
Pharmaceutical
The opioid use disorder market (OUD) is expected to experience solid growth over the next 10 years, expanding from $1.8 billion in 2017, to $4.8 billion in 2027 at a compound annual growth rate (CAGR) of 10.3%, says analyst. 26 November 2018
Pharmaceutical
In the USA alone, more than 10% of adults or adolescents take antidepressants, and fully two-thirds of these people do not respond to first-line treatment, normally a selective serotonin reuptake inhibitor (SSRI) such as Zoloft (sertraline) or Celexa (citalopram). 26 November 2018
Pharmaceutical
Swedish drugmaker Camurus (STO: CAMX) today said that the European Commission has granted marketing authorization for Buvidal (CAM2038), with news of the approval sending the firm’s shares soaring 9.38% to 89.80 Swedish kronor. 22 November 2018
Biotechnology
Weeks after a US Food and Drug Administration (FDA) panel overwhelmingly voted in support of the benefit-risk profile of Sage Therapeutics’ Zulresso (brexanolone) in postpartum depression (PPD), the agency has delayed a decision on whether to approve it. 21 November 2018
Pharmaceutical
Japanese drug major Astellas Pharma has announced the launch of the Astellas Global Health Foundation (AGHF), a new international philanthropic organization dedicated to improving access to health in underserved global communities. 21 November 2018
Biotechnology
As expected, following a positive recommendation from its advisory panel in September, the European Medicines Agency has granted approval for Emgality (galcanezumab), in the treatment of migraines. 19 November 2018
Pharmaceutical
Japanese pharma major Takeda Pharmaceutical has formed a drug discovery collaboration with Wales-based Cardiff University to identify new approaches for treating schizophrenia and other psychiatric disorders. 19 November 2018
Generics
Glenmark Pharmaceuticals has been granted final approval by the US Food and Drug Administration for teriflunomide tablets, 7mg and 14mg, a generic version of French pharma major Sanofi’s multiple sclerosis drug Aubagio. 16 November 2018
Biotechnology
US drugmaker AbbVie has teamed up with a UK drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs). 15 November 2018
Biotechnology
Eli Lilly’s 25 years spent researching headache disorders looks a little closer to paying off after a couple of announcements. 15 November 2018
Pharmaceutical
Generic drugmakers Actavis and Mylan have prevailed in a patent dispute against Warner-Lambert, part of the Pfizer group of companies. 14 November 2018
Pharmaceutical
Although the glioblastoma (GBM) treatment market is small with many unmet needs, it is expected to grow from $662.0 million in 2017 to $1.4 billion in 2027 across the eight major markets (8MM) at a compound annual growth rate (CAGR) of 7.5%. 12 November 2018
Pharmaceutical
Jazz Pharmaceuticals has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol. 9 November 2018
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to US biopharma Trevena in relation to the opioid painkiller, oliceridine. 5 November 2018
Biotechnology
US biopharma Sage Therapeutics looks all but certain to secure US approval for Zulresso (brexanolone) in postpartum depression after Food and Drug Administration (FDA) advisory committees supported its benefit-risk profile by 17 votes to one. 5 November 2018
Biotechnology
With 26 potential blockbusters in confirmatory development and 13 projects in clinical development across cell, gene and radioligand therapies, Swiss pharma giant Novartis says it plans to make 60 major regulatory submissions between 2019 and 2021. 5 November 2018
Pharmaceutical
Among deal-making news last week, pharma giants Novartis and Pfizer joined forces on the development of new NASH treatments with trialling of drugs in combination with the Swiss firm’s tropifexor. Also, Sanofi inked a collaboration with Denali on neurological diseases candidates DNL747 and DNL758. Interesting clinical trials results included encouraging new data on Grifols’ Alzheimer’s candidate Albutein were released by the Spanish drugmaker, and Genmab and Janssen announced positive findings on the flagship antibody Darzalex in myeloma. 4 November 2018
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze